Ipatasertib (IPAT) is an investigational, orally administered, ATP-competitive, highly selective inhibitor of pan AKT that has demonstrated anti-proliferative activity in pre-clinical models including prostate, breast, and ovarian cancers [17,18]. This evidence concerns the gene AKT1 and ovarian carcinoma.